ERBB2 and neoplasm: An ex vivo study revealed that tumor accumulation of CD8+ T cells induced by an anti-HER2 T-BsAb was suppressed to physiological levels by co-administration of a sphingosine 1-phosphate receptor agonist, which inhibits lymphocyte egress from secondary lymphoid organs and blocks trafficking between blood and tissue [71].